D44 - Many thanks for sharing! So in May, exclu
Post# of 7769
Posted On: 04/14/2014 10:37:38 AM
D44 - Many thanks for sharing!
So in May, excluding the DOD contract, we will have seven potential revenue streams, at least three of which will be generating revenues. Below are my projected revenues for each as well as my guesstimate on how much of each will hit SCRC's top line:
1. Specialty Pharmacy - $750,000 (at least $375,000 to SCRC per Bob's "significant percentage of revenues" statement in his recent PR)
2. WholesaleRx - $400,000 ($56,000 - 70% gross margin, 20% of gross margin to SCRC)
3. PIMD - $0 (unfortunately, we have no clue about these revenues from which SCRC is entitled to 90% of revenues)
4. RapiMed Hong Kong -$200,000 ($200,000 to SCRC, assumes no more orders in May)
5. RapiMed Mainland China - $0 (product approval possibly as early as June)
6. RapiMed Canada - $0 (no updates, probably nothing until the second half of 2014)
7. RapiMed US - $0 (not my favorite potential stream of revenue)
So in May, I am projecting revenues of $631,000 to SCRC. This alone is worth at least $.22 to the PPS. Just imagine where this stock will be in a year when all seven of these revenue streams are generating revenues.
It was also great to read your note that SCRC has only one more toxic note, which it intends to pay off in May, further supporting my opinion last month that Scrips is very close to being cash flow positive, assuming they are not there today. These are exciting times to be a Scrips shareholder. Indeed, how many penny stocks have survived 40 toxic convertible notes, over 8M shares dumped into the market by Ironridge, and transitioned to a multi-revenues generating, profit-making enterprise?? The rocket launch was delayed, not canceled!
BSAV
So in May, excluding the DOD contract, we will have seven potential revenue streams, at least three of which will be generating revenues. Below are my projected revenues for each as well as my guesstimate on how much of each will hit SCRC's top line:
1. Specialty Pharmacy - $750,000 (at least $375,000 to SCRC per Bob's "significant percentage of revenues" statement in his recent PR)
2. WholesaleRx - $400,000 ($56,000 - 70% gross margin, 20% of gross margin to SCRC)
3. PIMD - $0 (unfortunately, we have no clue about these revenues from which SCRC is entitled to 90% of revenues)
4. RapiMed Hong Kong -$200,000 ($200,000 to SCRC, assumes no more orders in May)
5. RapiMed Mainland China - $0 (product approval possibly as early as June)
6. RapiMed Canada - $0 (no updates, probably nothing until the second half of 2014)
7. RapiMed US - $0 (not my favorite potential stream of revenue)
So in May, I am projecting revenues of $631,000 to SCRC. This alone is worth at least $.22 to the PPS. Just imagine where this stock will be in a year when all seven of these revenue streams are generating revenues.
It was also great to read your note that SCRC has only one more toxic note, which it intends to pay off in May, further supporting my opinion last month that Scrips is very close to being cash flow positive, assuming they are not there today. These are exciting times to be a Scrips shareholder. Indeed, how many penny stocks have survived 40 toxic convertible notes, over 8M shares dumped into the market by Ironridge, and transitioned to a multi-revenues generating, profit-making enterprise?? The rocket launch was delayed, not canceled!
BSAV
(0)
(0)